{
  "id": 20751536,
  "title": "Regeneron Wins FDA Nod For Livsayis, 4x-Year GMG Shot",
  "url": "https://urgent.news/2026/11/19/regeneron-wins-fda-nod-for-livsayis-4x-year-gmg-shot",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-19T13:10:41.000Z",
  "source": {
    "name": "Benzinga",
    "slug": "benzinga",
    "url": "https://www.benzinga.com/news/fda/26/11/63423914/regeneron-wins-fda-nod-for-livsayis-4x-year-gmg-shot"
  },
  "original_language": "en",
  "account": "On Wednesday, the U.S. Food and Drug Administration (FDA) granted approval to Regeneron Pharmaceuticals Inc. for Livsayis, a four-times-yearly gene therapy targeting generalized myasthenia gravis (gMG) in adults with positive anti-acetylcholine receptor (AChR) antibodies. This marks the first and only FDA-approved small interfering RNA (siRNA) therapy for gMG, and the only treatment currently administered subcutaneously every four weeks. The innovative treatment targets complement component factor 5 (C5) to reduce circulating C5 protein levels and limit terminal complement activation, a primary cause of the disease. The FDA's approval was based on data from the Phase 3 NIMBLE trial, showing Livsayis achieved a 2.3-point improvement in the MG-ADL score at 24 weeks compared to a 2.2-point improvement for placebo. Additionally, 76.6% of Livsayis patients experienced at least a 3-point improvement in the MG-ADL score at 24 weeks, compared to 44.1% of placebo recipients. Livsayis also demonstrated significant gains in muscle function, with a 2.8-point placebo-adjusted benefit in the QMG scale at 24 weeks, compared to 1.5 points for placebo. The drug provided rapid symptom relief, with patients experiencing a clinically meaningful 2.5-point MG-ADL improvement within two weeks, which persisted throughout the 24-week study period without signs of diminishing efficacy.",
  "summary": "On Wednesday, the U.S. Food and Drug Administration approved Regeneron Pharmaceuticals Inc.’s (NASDAQ:REGN) Livsayis (cemdisiran) for generalized myasthenia gravis (gMG) in adults who test positive for anti-acetylcholine receptor (AChR) antibodies, the predominant form of the disease. Livsayis stands as the first and only approved small interfering RNA (siRNA) therapy for gMG. It also represents…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}